At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma: a Open-label, Randomized, Controlled Phase II Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, and 3 other interventions for Esophageal Squamous Cell Carcinoma and 2 related conditions. Active but no longer recruiting, targeting 170 participants across 1 site.
Detailed Summary
This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma
Study Details
Timeline
Interventions
Toripalimab 240mg iv. drip, Q3W, 2 cycles
Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.
Thoracic radiotherapy at a total dose of 50Gy was delivered using the intensity modulated radiation therapy technique.
Oral apatinib 250mg once daily during induction therapy and concurrent chemoradiotherapy.
Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy